Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Eine Studie zu TAK-279 bei erwachsenen Teilnehmern mit generalisierter pustulöser Psoriasis oder erythrodermischer Psoriasis

14. Oktober 2026 aktualisiert von: Takeda

Eine offene, multizentrische Phase-3-Studie zur Bewertung der Wirksamkeit, Sicherheit und Verträglichkeit von TAK-279 bei erwachsenen Patienten mit generalisierter Psoriasis pustulosa oder erythrodermischer Psoriasis

The main aim of this study is to check if TAK-279 improves symptoms of With Generalized Pustular Psoriasis (GPP) or Erythrodermic Psoriasis (EP) and side effect from the study treatment or TAK-279.

All participants will be assigned to study treatments of TAK-279 and will be treated with TAK-279 if the participants meet the study rules.

Participants will be in the study for up to 61 weeks including 52 weeks of study treatment. During the study, participants will visit their study clinic for multiple times.

Studienübersicht

Status

Abgeschlossen

Intervention / Behandlung

Studientyp

Interventionell

Einschreibung (Tatsächlich)

18

Phase

  • Phase 3

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

      • Fukuoka, Japan
        • Fukuoka University Hospital
      • Kyoto, Japan
        • University Hospital, Kyoto Prefectural University of Medicine
      • Okayama, Japan
        • Okayama University Hospital
      • Osaka, Japan
        • Nippon Life Hospital
      • Osaka, Japan
        • Osaka Metropolitan University Hospital
    • Aichi-ken
      • Nagoya, Aichi-ken, Japan
        • Nagoya City University Hospital
      • Toyoake, Aichi-ken, Japan
        • Fujita Health University Hospital
    • Chiba
      • Kisarazu, Chiba, Japan
        • Kimitsu Chuo Hospital
      • Urayasu, Chiba, Japan
        • Juntendo University Urayasu Hospital
    • Fukuoka
      • Kitakyushu, Fukuoka, Japan
        • Hospital of the University of Occupational and Environmental Health, Japan
    • Gunma
      • Isesaki, Gunma, Japan
        • Isesaki Municipal Hospital
    • Hyōgo
      • Kobe, Hyōgo, Japan
        • Kobe University Hospital
    • Kanagawa
      • Isehara, Kanagawa, Japan
        • Tokai University Hospital
    • Mie-ken
      • Tsu, Mie-ken, Japan
        • Mie University Hospital
    • Osaka
      • Hirakata, Osaka, Japan
        • Kansai Medical University Hospital
    • Saitama
      • Iruma, Saitama, Japan
        • Saitama Medical University Hospital
    • Tokyo
      • Chūō, Tokyo, Japan
        • St.Luke's International Hospital
      • Minato-ku, Tokyo, Japan
        • The Jikei University Hospital
      • Shinjuku-ku, Tokyo, Japan
        • Tokyo Medical University Hospital
      • tabashi City, Tokyo, Japan
        • Teikyo University Hospital

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  1. A diagnosis of GPP or EP prior to the screening visit.
  2. Candidate for phototherapy or systemic therapy.

Exclusion Criteria:

  1. Other forms of psoriasis.
  2. History of recent infection.
  3. Any prior exposure to TAK-279, or participation in any study that included a TYK2 inhibitor.

Other protocol defined inclusion/exclusion criteria apply.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Nicht randomisiert
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: TAK-279 for Generalized Pustular Psoriasis

Participants with generalized pustular psoriasis will receive TAK-279 from Day 1 up to Week 52.

Specified drug on specified days.

Experimental: TAK-279 for Erythrodermic Psoriasis

Participants with erythrodermic psoriasis will receive TAK-279 from Day 1 up to Week 52.

Specified drug on specified days.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Percentage of Participants Who Achieved a Static Physician's Global Assessment (sPGA) of Clear (0) or Almost Clear (1) With a Greater Than or Equal to (>=) 2-Point Decrease From Baseline at Week 16
Zeitfenster: At Week 16

The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scaling, and induration. The average of the 3 scales, rounded to the nearest whole number, is the final sPGA score. The sPGA score ranged from 0 to 4 (0 = Clear; 1 = Almost clear; 2 = Mild; 3 = Moderate; 4 = Severe). Higher scores indicated more severe disease activity. 'Clear' and 'Almost clear' included all participants who scored a 0 or 1.

At Week 16
Percentage of Participants Who Achieved >=75 Percent (%) Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 16
Zeitfenster: At Week 16

PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produced a numeric score that ranged from 0 to 72, with higher PASI scores denoting more severe disease activity. Percentage of participants showing at least 75% improvement in PASI score relative to baseline PASI score were reported.

At Week 16

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Percentage of Participants Who Achieved an sPGA of Clear (0) or Almost Clear (1) With a >=2-Point Decrease From Baseline at Week 52
Zeitfenster: At Week 52

The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scaling, and induration. The average of the 3 scales, rounded to the nearest whole number, is the final sPGA score. The sPGA score ranged from 0 to 4 (0 = Clear; 1 = Almost clear; 2 = Mild; 3 = Moderate; 4 = Severe). Higher scores indicated more severe disease activity. 'Clear' and 'Almost clear' included all participants who scored a 0 or 1. The results will be disclosed during final posting.

At Week 52
Percentage of Participants Who Achieved an sPGA of Clear (0) or Almost Clear (1) With a >=2-Point Decrease From Baseline at Both Weeks 16 and 52
Zeitfenster: At both Weeks 16 and 52

The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scaling, and induration. The average of the 3 scales, rounded to the nearest whole number, is the final sPGA score. The sPGA score ranged from 0 to 4 (0 = Clear; 1 = Almost clear; 2 = Mild; 3 = Moderate; 4 = Severe). Higher scores indicated more severe disease activity. 'Clear' and 'Almost clear' included all participants who scored a 0 or 1. The results will be disclosed during final posting.

At both Weeks 16 and 52
Percentage of Participants Who Achieved an sPGA of Clear (0) at Weeks 16 and 52
Zeitfenster: At Weeks 16 and 52

The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scaling, and induration. The average of the 3 scales, rounded to the nearest whole number, is the final sPGA score. The sPGA score ranged from 0 to 4 (0 = Clear; 1 = Almost clear; 2 = Mild; 3 = Moderate; 4 = Severe). Higher scores indicated more severe disease activity. 'Clear' and 'Almost clear' included all participants who scored a 0 or 1. The results will be disclosed during final posting.

At Weeks 16 and 52
Percentage of Participants Who Achieved an sPGA of Clear (0) or Almost Clear (1) at Weeks 16 and 52
Zeitfenster: At Weeks 16 and 52

The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scaling, and induration. The average of the 3 scales, rounded to the nearest whole number, is the final sPGA score. The sPGA score ranged from 0 to 4 (0 = Clear; 1 = Almost clear; 2 = Mild; 3 = Moderate; 4 = Severe). Higher scores indicated more severe disease activity. 'Clear' and 'Almost clear' included all participants who scored a 0 or 1. The results will be disclosed during final posting.

At Weeks 16 and 52
Percentage of Participants Who Achieved an sPGA of Clear (0) or Almost Clear (1) at Both Weeks 16 and 52
Zeitfenster: At both Weeks 16 and 52

The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scaling, and induration. The average of the 3 scales, rounded to the nearest whole number, is the final sPGA score. The sPGA score ranged from 0 to 4 (0 = Clear; 1 = Almost clear; 2 = Mild; 3 = Moderate; 4 = Severe). Higher scores indicated more severe disease activity. 'Clear' and 'Almost clear' included all participants who scored a 0 or 1. The results will be disclosed during final posting.

At both Weeks 16 and 52
Percentage of Participants Who Achieved PASI-75 at Week 52
Zeitfenster: At Week 52

PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produced a numeric score that ranged from 0 to 72, with higher PASI scores denoting more severe disease activity. Percentage of participants showing at least 75% improvement in PASI score relative to baseline PASI score are reported. The results will be disclosed during final posting.

At Week 52
Percentage of Participants Who Achieved PASI-90 at Weeks 16 and 52
Zeitfenster: At Weeks 16 and 52

PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produced a numeric score that ranged from 0 to 72, with higher PASI scores denoting more severe disease activity. Percentage of participants showing at least 90% improvement in PASI score relative to baseline PASI score are reported. The results will be disclosed during final posting.

At Weeks 16 and 52
Percentage of Participants Who Achieved PASI-100 at Weeks 16 and 52
Zeitfenster: At Weeks 16 and 52

PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produced a numeric score that ranged from 0 to 72, with higher PASI scores denoting more severe disease activity. Percentage of participants showing 100% improvement in PASI score relative to baseline PASI score are reported. The results will be disclosed during final posting.

At Weeks 16 and 52
Percentage of Participants Who Achieved PASI-75 at Both Weeks 16 and 52
Zeitfenster: At both Weeks 16 and 52

PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produced a numeric score that ranged from 0 to 72, with higher PASI scores denoting more severe disease activity. Percentage of participants showing at least 75% improvement in PASI score relative to baseline PASI score are reported. The results will be disclosed during final posting.

At both Weeks 16 and 52
Percentage of Participants Who Achieved PASI-90 at Both Weeks 16 and 52
Zeitfenster: At both Weeks 16 and 52

PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produced a numeric score that ranged from 0 to 72, with higher PASI scores denoting more severe disease activity. Percentage of participants showing at least 90% improvement in PASI score relative to baseline PASI score are reported. The results will be disclosed during final posting.

At both Weeks 16 and 52
Percentage of Participants Who Achieved a Scalp-specific Physician's Global Assessment (ssPGA) of Absence of Disease (0) or Very Mild Disease (1) With a >=2-Point Decrease From Baseline at Weeks 16 and 52
Zeitfenster: At Weeks 16 and 52

ssPGA assesses the overall severity of active psoriasis on the participant's scalp. Scalp lesions were evaluated in terms of clinical signs of erythema, induration, and scaling and scored on 5-point ssPGA scale where 0=absence of disease and 4=severe disease. Higher scores indicated worsening. The results will be disclosed during final posting.

At Weeks 16 and 52
Change From Baseline in ssPGA at Weeks 16 and 52
Zeitfenster: Baseline, Weeks 16 and 52

ssPGA assesses the overall severity of active psoriasis on the participant's scalp. Scalp lesions were evaluated in terms of clinical signs of erythema, induration, and scaling and scored on 5-point ssPGA scale where 0=absence of disease and 4=severe disease. Higher scores indicated worsening. The results will be disclosed during final posting.

Baseline, Weeks 16 and 52
Percentage of Participants Who Achieved a PGA of the Hands and/or Feet of Clear (0) or Almost Clear (1) With a >=2-Point Decrease From Baseline at Weeks 16 and 52
Zeitfenster: At Weeks 16 and 52

PGA is a 5-point scale and a score of 0 to 4 was assigned, based on the category that best described the severity of active psoriasis of the participant's hands and feet, where 0=clear and 4=severe. Higher scores indicated worsening of severity. It was evaluated for participants with the presence of active hand or foot psoriasis on Day 1. The results will be disclosed during final posting.

At Weeks 16 and 52
Percentage of Participants With a Baseline Dermatology Life Quality Index (DLQI) Score >=2 Who Achieved DLQI Score of 0 or 1 at Weeks 16 and 52
Zeitfenster: At Weeks 16 and 52

The DLQI is a 10-item validated questionnaire completed by the participant or caregiver used to assess the impact of skin disease on the participant's quality of life (QoL) during the previous week. The 10 questions cover the following topics: symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, and treatment. Each question is scored from 0=not at all, 1=a little, 2=a lot, and 3=very much, giving a total score ranging from 0 to 30. A high score is indicative of a poor QoL. DLQI scores indicated: 0-1 (no effect on participant's life), 2-5 (small effect on participant's life), 6-10 (moderate effect on participant's life), 11-20 (very large effect on participant's life), 21-30 (extremely large effect on participant's life). The results will be disclosed during final posting.

At Weeks 16 and 52
Change From Baseline in DLQI at Weeks 16 and 52
Zeitfenster: Baseline, Weeks 16 and 52

The DLQI is a 10-item validated questionnaire completed by the participant or caregiver used to assess the impact of skin disease on the participant's quality of life (QoL) during the previous week. The 10 questions cover the following topics: symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, and treatment. Each question is scored from 0=not at all, 1=a little, 2=a lot, and 3=very much, giving a total score ranging from 0 to 30. A high score is indicative of a poor QoL. DLQI scores indicated: 0-1 (no effect on participant's life), 2-5 (small effect on participant's life), 6-10 (moderate effect on participant's life), 11-20 (very large effect on participant's life), 21-30 (extremely large effect on participant's life). The results will be disclosed during final posting.

Baseline, Weeks 16 and 52
Change From Baseline in Nail Psoriasis Severity Index (NAPSI) at Weeks 16 and 52 Among Participants With Nail Involvement at Baseline
Zeitfenster: Baseline, Weeks 16 and 52

The NAPSI quantifies the severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on the lunula, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop [salmon patch dyschromia]). Each nail was scored for both nail matrix and nail bed psoriasis for each quadrant (ranging from 0 [absence of psoriasis] to 4 [presence of psoriasis in all 4 quadrants]). The total NAPSI score equals the sum of scores for all fingernails evaluated and ranged from 0 to 80. Higher scores indicated more severe psoriasis. The results will be disclosed during final posting.

Baseline, Weeks 16 and 52
Change From Baseline in Body Surface Area (BSA) Affected by Psoriasis at Weeks 16 and 52
Zeitfenster: Baseline, Weeks 16 and 52

Psoriasis BSA was assessed by means of the handprint method, where the surface of the palm and 5 digits of the participant's hand represented 1% BSA. The sum of handprints equated to the total surface area of involvement. The results will be disclosed during final posting.

Baseline, Weeks 16 and 52
Percent Change From Baseline in BSA Affected by Psoriasis at Weeks 16 and 52
Zeitfenster: Baseline, Weeks 16 and 52

Psoriasis BSA was assessed by means of the handprint method, where the surface of the palm and 5 digits of the participant's hand represented 1% BSA. The sum of handprints equated to the total surface area of involvement. The results will be disclosed during final posting.

Baseline, Weeks 16 and 52
Percentage of Participants With Generalized Pustular Psoriasis Who Achieved a Generalized Pustular Psoriasis Global Assessment (GPPGA) Pustulation Subscore of No Visible Pustules (0) at Weeks 16 and 52
Zeitfenster: At Weeks 16 and 52

The GPPGA is a common endpoint in clinical studies of GPP and is a skin-based scoring system. The GPPGA is a clinician assessment of overall GPP severity based on a modified PGA. The severity of pustules, erythema, and scaling of GPP lesions was assessed. The 5 grades of severity for erythema, scaling, and pustulation corresponded to 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe. The GPPGA score was based on averaging the individual scores for erythema, scaling, and pustulation and ranged from 0 to 4. Higher scores indicated more severe GPP. The results will be disclosed during final posting.

At Weeks 16 and 52
Percentage of Participants With Generalized Pustular Psoriasis Who Achieved a GPPGA of Clear (0) or Almost Clear (1) at Weeks 16 and 52
Zeitfenster: At Weeks 16 and 52

The GPPGA is a common endpoint in clinical studies of GPP and is a skin-based scoring system. The GPPGA is a clinician assessment of overall GPP severity based on a modified PGA. The severity of pustules, erythema, and scaling of GPP lesions was assessed. The 5 grades of severity for erythema, scaling, and pustulation corresponded to 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe. The GPPGA score was based on averaging the individual scores for erythema, scaling, and pustulation and ranged from 0 to 4. Higher scores indicated more severe GPP. The results will be disclosed during final posting.

At Weeks 16 and 52
Percentage of Participants With Generalized Pustular Psoriasis Who Achieved a GPPGA of Clear (0) at Weeks 16 and 52
Zeitfenster: At Weeks 16 and 52

The GPPGA is a common endpoint in clinical studies of GPP and is a skin-based scoring system. The GPPGA is a clinician assessment of overall GPP severity based on a modified PGA. The severity of pustules, erythema, and scaling of GPP lesions was assessed. The 5 grades of severity for erythema, scaling, and pustulation corresponded to 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe. The GPPGA score was based on averaging the individual scores for erythema, scaling, and pustulation and ranged from 0 to 4. Higher scores indicated more severe GPP. The results will be disclosed during final posting.

At Weeks 16 and 52
Percentage of Participants With Generalized Pustular Psoriasis Who Achieved >=75% Improvement From Baseline in Generalized Pustular Psoriasis Area and Severity Index (GPPASI) Score at Weeks 16 and 52
Zeitfenster: At Weeks 16 and 52

The GPPASI is a common endpoint in clinical studies of generalized pustular psoriasis (GPP) and is a skin-based scoring system. The GPPASI is a modified composite index and an adaptation of the PASI score. The induration component was substituted with a pustule component, with an overall score ranging from 0 (least severe) to 72 (most severe). Higher scores indicated more severe GPP. The 5 grades of severity for erythema, scaling, and pustulation corresponded to 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe. The score for each body region was calculated as the product of the sum of severity scores and the corresponding BSA score for erythema, scaling, and pustulation, multiplied by a weighting factor for each body region. The total GPPASI score was determined as the sum of the individual scores from all body regions. The results will be disclosed during final posting.

At Weeks 16 and 52
Change From Baseline in Japanese Dermatological Association Severity Index (JDASI) Score at Weeks 16 and 52 for Participants With Generalized Pustular Psoriasis
Zeitfenster: At Weeks 16 and 52

The Japanese Dermatological Association Severity Index (JDASI) assessed systemic symptoms based on laboratory changes. With the JDASI, the skin was evaluated using 3 criteria: (1) erythema area overall, (2) erythema area with pustules, and (3) oedema area. Scoring ranged from 3 to 0 (severe, moderate, mild, none), with a maximum of 9 points. For systemic involvement, pyrexia, white blood cell count, C-reactive protein (CRP), and serum albumin were assessed, with scores ranging from 2 to 0 and a maximum of 8 points. The total JDASI score for GPP was the sum of both categories and was categorized as severe (17-11 points), moderate (10-7 points), or mild (0-6 points). Higher scores indicated more severe GPP. The results will be disclosed during final posting.

At Weeks 16 and 52

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Ermittler

  • Studienleiter: Study Director, Takeda

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

19. März 2024

Primärer Abschluss (Tatsächlich)

17. Oktober 2025

Studienabschluss (Tatsächlich)

10. Juli 2026

Studienanmeldedaten

Zuerst eingereicht

15. März 2024

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

15. März 2024

Zuerst gepostet (Tatsächlich)

21. März 2024

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

4. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

14. Oktober 2026

Zuletzt verifiziert

1. Oktober 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • TAK-279-PsO-3005
  • jRCT2031230714 (Registrierungskennung: jRCT)

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

IPD-Sharing-Zugriffskriterien

IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Art der unterstützenden IPD-Freigabeinformationen

  • STUDIENPROTOKOLL
  • SAFT
  • ICF
  • CSR

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Produkt, das in den USA hergestellt und aus den USA exportiert wird

Ja

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren